Can pharmacy training boost HPV shots and prevent future cancers?
NCT ID NCT06926062
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 6 times
Summary
This study looks at whether training pharmacy staff to better communicate about and manage the HPV vaccine can increase vaccination rates in children ages 9-17. About 1,900 participants, including pharmacy staff and parents, will be involved. The goal is to make it easier for families to get the HPV vaccine at pharmacies, which could help prevent HPV-related cancers later in life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,900 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * OBJECTIVE 1: Adults aged 18 years or older who live in the 50 United States (U.S.) states and Washington District of Columbia (D.C.) and are parents or guardians of children ages 9-17 are eligible to take the national survey (n ≤ 1,600, with anticipated enrollment of n = \~1,500) * OBJECTIVE 2: Pharmacy staff at participating pharmacies (n ≤ 100) * OBJECTIVE 2: Adults aged 18 years or older whose children ages 9-17 received an HPV vaccine at one of the participating pharmacies in study year 2 (n ≤ 200) Exclusion Criteria: * OBJECTIVE 1: Non-English speaking as the survey is only available for this project in English * OBJECTIVE 1: Parents whose index children have completed the HPV vaccine series * OBJECTIVE 2: Non-English speaking as the study funding only provided resources for surveys and interview materials to be available in English * OBJECTIVE 2: Parents whose index children have completed the HPV vaccine series
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Human papillomavirus-related carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
-
Penn State University
NOT_YET_RECRUITINGUniversity Park, Pennsylvania, 16802, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple education push prevent 400,000 cancers?
- At-Home cervical cancer screening could save lives in rural uganda
- Could a delayed booster still protect against HPV?
- Free HPV shots help prevent cancer in Low-Income adults
- Engineered immune cells take on HPV cancers in early trial
- Can a Pre-Transplant HPV shot shield patients from cancer?